Diametric Capital, LP Biomarin Pharmaceutical Inc Transaction History

Diametric Capital, LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 13, 2020	SELL	$71.87 - $131.03 $362,368 - $660,653	-5,042 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$79.55 - $124.22 $87,425 - $136,517	1,099 Added 27.87%	5,042 $622,000
Q1 2020 May 15, 2020	SELL	$71.37 - $96.85 $1.04 Million - $1.4 Million	-14,506 Reduced 78.63%	3,943 $333,000
Q4 2019 Feb 14, 2020	BUY	$64.27 - $86.37 $1.19 Million - $1.59 Million	18,449 New	18,449 $1.56 Million
Q4 2018 Feb 14, 2019	SELL	$80.14 - $106.07 $565,948 - $749,066	-7,062 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$93.92 - $105.72 $663,263 - $746,594	7,062 New	7,062 $685,000

632

185M

1.63M

1.2M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $13.1B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Diametric Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Diametric Capital, LP with notifications on news.